Urania Dafni

Urania Dafni

Auto-generated profile, based on publicly available information

Urania Dafni

ETOP Statistical Center, Frontier Science Foundation-Hellas & University of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
NCN. I. Cherny
N. I. Cherny
RSR. Sullivan
R. Sullivan
UDU. Dafni
U. Dafni
JKJ. M. Kerst
J. M. Kerst
ASA. Sobrero
A. Sobrero
MPM. J. Piccart
M. J. Piccart
The value of any new therapeutic strategy or treatment is determined by the magnitude of its clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment options is derived from clinical research, in particular phase III randomised trials, which generate unbiased data regarding the efficacy, benefit and safety of new therapeutic approaches. To date, there is no standard tool for grading the magnitude of clinical benefit of cancer therapies, which may range from trivial (median progression-free survival advantage of only a few weeks) to substantial (improved long-term survival). Indeed, in the absence of a standardised approach for grading the magnitude of clinical benefit, conclusions and recommendations derived from studies are often hotly disputed and very modest incremental advances have often been presented, discussed and promoted as major advances or ‘breakthroughs’. Recognising the importance of presenting clear and unbiased statements regarding the magnitude of the clinical benefit from new therapeutic approaches derived from high-quality clinical trials, the European Society for Medical Oncology (ESMO) has developed a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). This tool uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from a new anti-cancer treatment. The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care. The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis.

1 May 2011 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
UDUrania Dafni
Urania Dafni
This statistical primer presents the landmark analysis method, exploring its appropriate use and interpretation while recognizing its limitations. This observational method is used for comparing time-to-event outcome between groups determined during study follow-up. The goal of the landmark method is to estimate in an unbiased way the time-to-event probabilities in each group conditional on the group membership of patients at a specific time point, the landmark time. The need that led to its development, the impact of the method, and its pros and cons, along with available alternative approaches, are presented. Simulations explore its performance, using realistic parameters from a recent cardiovascular study. As long as the limitations of the method are recognized and the interpretation of its results clearly reflect their “conditional” nature, landmark analysis, 25 years from its introduction, can still be of value.

4 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
NCN. I. Cherny
N. I. Cherny
UDU. Dafni
U. Dafni
JBJ. Bogaerts
J. Bogaerts
NLN. J. Latino
N. J. Latino
GPG. Pentheroudakis
G. Pentheroudakis
GVGrietje Knol-de Vries
Grietje Knol-de Vries
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies. The ESMO-MCBS was designed to be a dynamic tool with planned revisions and updates based upon recognition of expanding needs and shortcomings identified since the last review. The revision process for the ESMO-MCBS incorporates a nine-step process: Careful review of critiques and suggestions, and identification of problems in the application of v1.0; Identification of shortcomings for revision in the upcoming version; Proposal and evaluation of solutions to address identified shortcomings; Field testing of solutions; Preparation of a near-final revised version for peer review for reasonableness by members of the ESMO Faculty and Guidelines Committee; Amendments based on peer review for reasonableness; Near-final review by members of the ESMO-MCBS Working Group and the ESMO Executive Board; Final amendments; Final review and approval by members of the ESMO-MCBS Working Group and the ESMO Executive Board. Twelve issues for revision or amendment were proposed for consideration; proposed amendments were formulated for eight identified shortcomings. The proposed amendments are classified as either structural, technical, immunotherapy triggered or nuanced. All amendments were field tested in a wide range of studies comparing scores generated with ESMO-MCBS v1.0 and version 1.1 (v1.1). ESMO-MCBS v1.1 incorporates 10 revisions and will allow for scoring of single-arm studies. Scoring remains very stable; revisions in v1.1 alter the scores of only 12 out of 118 comparative studies and facilitate scoring for single-arm studies.

1 March 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
LGLuca Gianni
Luca Gianni
UDUrania Dafni
Urania Dafni
RGRichard D Gelber
Richard D Gelber
EAEvandro de Azambuja
Evandro de Azambuja
SMSusanne Muehlbauer
Susanne Muehlbauer
HTHerceptin Adjuvant (HERA) Trial Study Team
Herceptin Adjuvant (HERA) Trial Study Team

16 February 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
HGHelen Gogas
Helen Gogas
JIJohn Ioannovich
John Ioannovich
UDUrania Dafni
Urania Dafni
CSCatherine Stavropoulou-Giokas
Catherine Stavropoulou-Giokas
KFKonstantina Frangia
Konstantina Frangia
JKJohn M. Kirkwood
John M. Kirkwood
Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b.

3 September 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
FHFernanda G. Herrera
Fernanda G. Herrera
CRCatherine Ronet
Catherine Ronet
MOMaria Ochoa de Olza
Maria Ochoa de Olza
DBDavid Barras
David Barras
ICIsaac Crespo
Isaac Crespo
GCGeorge Coukos
George Coukos
Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4+ and CD8+ T cells. LDRT elicited predominantly CD4+ cells with features of exhausted effector cytotoxic cells, with a subset expressing NKG2D and exhibiting proliferative capacity, as well as a unique subset of activated dendritic cells expressing the NKG2D ligand RAE1. We translated these findings to a phase I clinical trial administering LDRT, low-dose cyclophosphamide, and immune checkpoint blockade to patients with immune-desert tumors. In responsive patients, the combinatorial treatment triggered T-cell infiltration, predominantly of CD4+ cells with Th1 signatures. Our data support the rational combination of LDRT with immunotherapy for effectively treating low T cell–infiltrated tumors. Significance: Low-dose radiation reprogrammed the tumor microenvironment of tumors with scarce immune infiltration and together with immunotherapy induced simultaneous mobilization of innate and adaptive immunity, predominantly CD4+ effector T cells, to achieve tumor control dependent on NKG2D. The combination induced important responses in patients with metastatic immune-cold tumors. This article is highlighted in the In This Issue feature, p. 1